CJC-1295 NO DAC 5mg

CJC-1295 NO DAC (Mod GRF 1-29) peptide 5 mg – Research Overview

CJC-1295 NO DAC, also known as Mod GRF 1-29, is a synthetic research-grade peptide identical to a naturally occurring fragment of Growth Hormone–Releasing Hormone (GHRH). This peptide consists of a shortened 29–amino-acid sequence and does not contain a Drug Affinity Complex (DAC). Therefore, CJC-1295 NO DAC exhibits a short and pulsatile activity profile, which makes it suitable for experimental research focused on physiological hormone signaling dynamics.

Researchers study CJC-1295 NO DAC peptide in experimental models focused on hypothalamic–pituitary communication and growth hormone–related signaling pathways. In this context, laboratory models allow scientists to observe how biological systems respond to brief, well-defined signaling pulses rather than prolonged stimulation. At the same time, these studies help clarify how timing and frequency influence endocrine regulation.

Originally developed in the 1980s, Mod GRF 1-29 gained relevance as a reference peptide for studying GHRH-related mechanisms. As a result, it remains widely used in basic research settings that require precise control over signaling duration and intensity.

CJC-1295 NO DAC peptide in pulsatile signaling research

In preclinical research, scientists frequently reference CJC-1295 NO DAC peptide in experimental models examining short-acting growth hormone signaling patterns. Additionally, these models support investigation of how endocrine systems coordinate pulsatile communication and feedback regulation under controlled conditions.

Researchers also study CJC-1295 NO DAC peptide in laboratory environments focused on metabolic signaling and adaptive regulatory responses. Through these studies, research teams analyze how short-lived signaling events influence energy balance, tissue-related signaling, and systemic coordination.

Moreover, CJC-1295 NO DAC peptide appears in experimental research related to regenerative signaling and physiological adaptation models. These studies allow scientists to explore how biological systems maintain responsiveness and flexibility during repeated signaling cycles.

CJC-1295 NO DAC compared to DAC-modified variants

Unlike CJC-1295 with DAC, the NO DAC variant lacks albumin-binding capability. Consequently, its activity remains brief and rapidly cleared from experimental systems. Researchers often select CJC-1295 NO DAC peptide when studies require high temporal resolution rather than prolonged signaling exposure.

In comparative research environments, scientists frequently evaluate CJC-1295 NO DAC alongside DAC-modified analogs. This approach supports deeper understanding of differences between short-acting and long-acting GHRH-based signaling models.

Public scientific databases, including PubChem, provide biochemical and molecular reference data for CJC-1295 NO DAC peptide. Accordingly, researchers rely on these standardized resources when designing experimental protocols and validating laboratory research data.

Research handling and laboratory use

Laboratories handle CJC-1295 NO DAC peptide exclusively in controlled research environments. Additionally, appropriate storage conditions and standardized handling procedures help maintain peptide stability and molecular integrity. In turn, consistent laboratory protocols support reliable and reproducible experimental outcomes.

Therefore, all research involving CJC-1295 NO DAC peptide remains limited to in vitro and preclinical laboratory research models. Accordingly, these activities do not include clinical, therapeutic, hormonal, or diagnostic use.

Important Notice

This product is intended exclusively for laboratory and scientific research purposes.
Not intended for human or veterinary use.
Not intended for diagnostic, therapeutic, or clinical applications.